The fact that Valeant is considering selling Salix — one of its few high-margin, high-growth divisions — at a substantial discount suggests "non-core" divestitures won't save Valeant from its debt woes. Similarly, the eye-surgery unit is part of Valeant's once-untouchable Bausch & Lomb division. The fact it's also up for sale is another bad sign.